Peptide vaccines against interleukin-31
AssigneeZoetis Services LLC
InventorsGary Francis Bammert, Steven Alan Dunham
Life of this patent
Estimating the term…
Abstract
A vaccine composition for immunizing and/or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.
Claims20
A vaccine composition for immunizing and/or protecting a mammal against an interleukin-31 (IL-31) mediated disorder, wherein said composition comprises:
- a) the combination of a carrier polypeptide and at least one IL-31 mimotope, wherein said IL-31 mimotope is:
- i) a parent equine IL-31 mimotope which is a peptide from about 5 to about 40 amino acid residues in length and is and/or comprises as part thereof an amino acid sequence selected from the group consisting of SMPTDNFERKRF (SEQ ID NO:
- 189), NSSAILPYFKAISPSLNNDKSL YIIEQLDKLNF (SEQ ID NO:
- 194), GPIYQLQPKEIQAIIVELQNLSKK (SEQ ID NO:
- 198), and KGVQKF (SEQ ID NO:
- 202);
- or
- ii) a variants IL-31 mimotope which is a peptide from about 5 to about 40 amino acid residues in length that has at least 50% amino acid sequence identity with said parent equine IL-31 mimotope and is and/or comprises the amino acid sequence of said parent equine IL-31 mimotope except for one or more amino acid substitutions within said amino acid sequence, wherein said variant IL-31 mimotope retains anti-IL-31 binding;
- and
- b) an adjuvant.
Dependencies are inferred from the claim text.